Gefitinib maintenance therapy in Chinese advanced-stage lung adenocarcinoma patients with EGFR mutations treated with prior chemotherapy

Rok, strany: 2015, 302 - 307

The aim of this study was to determine the response of advanced-stage non-small cell lung cancer (NSCLC) patients with or without EGFR mutations to platinum-based chemotherapy with or without gefitinib maintenance. Patients were treated with four cycles of platinum-based chemotherapy. Patients with wild-type EGFR were observed (group 1; n=15). EGFR mutation-positive patients were randomly assigned to observation (group 2; n=7) or gefitinib maintenance (group 3; n=7). The median patient age was 59 years. The 1-year progression-free survival rates in groups 1, 2, and 3 were 6.7%, 28.6%, and 57.1%, respectively (p = 0.049); the 1-year overall survival rates were 53.3%, 57.1 %, and 100%, respectively (p = 0.111). The results indicate that patients with advanced-stage NSCLC with EGFR mutations have a better response to chemotherapy followed by gefitinib than chemotherapy alone and a better response to chemotherapy than wild-type patients. Keywords: chemotherapy, gefitinib, NSCLC, tyrosine kinase inhibitors

ISO 690:

Cai, K., Liu, D., Wang, Y., Wu, H., Huang, Z., Cai, R., Wang, H., Xiong, G., Zhang, Z. 2015. Gefitinib maintenance therapy in Chinese advanced-stage lung adenocarcinoma patients with EGFR mutations treated with prior chemotherapy. In NEOPLASMA, vol. 62, no.2, pp. 302-307. 0028-2685.

APA:

Cai, K., Liu, D., Wang, Y., Wu, H., Huang, Z., Cai, R., Wang, H., Xiong, G., Zhang, Z. (2015). Gefitinib maintenance therapy in Chinese advanced-stage lung adenocarcinoma patients with EGFR mutations treated with prior chemotherapy. NEOPLASMA, 62(2), 302-307. 0028-2685.